Psilocybin
OpenAlex – May 01, 2025
Source: OpenAlex
Summary
Psilocybin, a potent hallucinogen derived from over 200 mushroom species, is demonstrating significant promise in psychology. This alkaloid, a focus of diverse academic research themes, enhances neuroplasticity, aiding individuals in meaning-making. Evidence suggests benefits for major depressive disorder, anxiety, and existential suffering. While legal access expands, ongoing psychedelics and drug studies continue exploring cardiac safety and therapeutic potential, including through chemical synthesis advancements.
Abstract
Abstract Psilocybin, a naturally occurring psychoactive compound found in more than 200 mushroom species, has an enduring history of use in sacred rituals of Indigenous healers worldwide. With selective serotonin receptor binding, activation of the serotonergic neurological system enables psilocybin to potentiate neuroplasticity, enabling individuals to engage in meaning-making from psychedelic experiences. There is growing evidence of benefit in major depressive disorder, anxiety disorders, existential suffering/demoralization, and promise in substance use disorders. Dosing ranges from lower “psycholytic” doses to higher “psychoactive” doses. Although there is low evidence of physiological harm to humans, further studies are needed to explore cardiac and neurological safety in diverse and vulnerable populations. Legal access is expanding through decriminalization, legalization, and “right-to-try” approaches, depending on the country and region. Future directions include expanded research; equitable access for vulnerable populations; reciprocity for Indigenous populations; and ensuring palliative patients, caregivers, and health care providers benefit from ethical and transparent research and clinical practice.